Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL -- Ignore unavailable to you. Want to Upgrade?

To: biowa who wrote (497)	2/2/2000 9:49:00 AM
From: Biomaven	Read Replies (2) \| Respond to of 666

Well CLTR +4 and IDPH -20 as I write. May also be related to news that the Zevalin NDA will be delayed to the fourth quarter 2000. Here's the claim for the new patent. Note that Y-90 is explicitly mentioned. 1. A composition comprising: (1) a radioactively labelled monoclonal antibody or radioactively labelled monoclonal antibody fragment in an amount providing 1 to 200 mCi of radioactivity and providing irradiation in a dose range of 10 to 200 cGy to the whole body of a human patient, said amount being effective for achieving remission of B-cell lymphoma in the patient, wherein said antibody or said antibody fragment binds to CD20 antigen present on the surface of cells of B-cell lymphoma and wherein the amount of radioactivity that labels the antibody or antibody fragment is less than the amount which causes myelosuppression severe enough to require the reintroduction of hematopoietic stem cells into said patient in order for the patient to recover hematopoietic function, and (2) a pharmaceutically acceptable carrier. 2. The composition of claim 1, wherein the radioactively labelled monoclonal antibody or radioactively labelled monoclonal antibody fragment is labelled with a .beta.-emitter. 3. The composition of claim 2, wherein the radioactively labelled monoclonal antibody or radioactively labelled monoclonal antibody fragment is labelled with an isotope selected from the group consisting of .sup.131, .sup.90 Y, .sup.188 Re, and .sup.186 Re. 4. The composition of claim 1, wherein the amount of the radioactively labelled monoclonal antibody or radioactively labelled monoclonal antibody fragment provides irradiation in a dose range of 15 to 150 cGy to the whole body of the patient. 5. The composition of claim 4, wherein the amount of the radioactively labelled monoclonal antibody or radioactively labelled monoclonal antibody fragment provides irradiation in a dose range of 25 to 100 cGy to the whole body of the patient. 6. The composition of claim 5, wherein the amount of the radioactively labelled monoclonal antibody or radioactively labelled monoclonal antibody fragment provides an irradiation dose of 75 cGy to the whole body of the patient. 7. The composition of claim 1, wherein the amount of the radioactively labelled monoclonal antibody or radioactively labelled monoclonal antibody fragment is an amount providing 1 to 150 mCi of radioactivity. 8. The composition of claim 7, wherein the amount of the radioactively labelled monoclonal antibody or radioactively labelled monoclonal antibody fragment is an amount providing 1 to 100 mCi of radioactivity. 9. The composition of claim 3, wherein the isotope is .sup.131 I. 10. The composition of claim 3, wherein the isotope is .sup.90 Y. 11. The composition of claim 1, wherein the radioactively labeled monoclonal antibody or radioactively labeled monoclonal antibody fragment has a specific activity in a range of 1 to 10 mCi/mg. 12. The composition of claim 1 wherein the amount of the radioactively labeled monoclonal antibody or radioactively labeled monoclonal antibody fragment has sufficient affinity and specific activity to deliver 10.6+/-2.76 cGy/mCi to a tumor targeted by the antibody or antibody fragment when administered to a patient. Peter

To: biowa who wrote (497)	2/2/2000 10:06:00 AM
From: Vector1	Read Replies (1) \| Respond to of 666

Biowa, I just finished reading the patent and it looks damm broad, on its face clearly covering Zev. You can bet the patent lawyers at IDEC are burning the candles looking for an attack. The key question in the US is time of discovery which we can not know for certain. Hopefully the CLTR people have good lab notes. However, I caution that we do not know what applications if any that IDPH has filed or how far back they can document their work in this area. It strikes me the most likely scenerio is a licence agreement with IDPH and CLTR resulting in both some nice downside protection if CLTR keeps having its BLA problems. The upside of course is a double digit royalty on Y2B8. V1